Adherium has commenced production and market release of the new GSK pMDI sensors

Latest News

Adherium (ASX:ADR) has commenced production and market release of its new Hailie sensors with physiological parameters connecting GSK product inhalers for monitoring Asthma and Chronic Obstructive Pulmonary Disease (COPD).

CEO Rick Legleiter said, “Purchase orders are in house with a fast growing pipeline for our sensors with expanded data capabilities. This latest market release expands the portfolio by adding more inhalers covered with physiological parameter capabilities. I am excited for patients and for commercial focus with our business partners.”

Adherium said its platform’s physiological parameters offer enhanced monitoring services for patients with severe, uncontrolled, and difficult-to-treat respiratory diseases, providing opportunities to improve patient management, increase responsiveness to exacerbations and ultimately reduce hospitalisations. 

Hailie enables doctors to bill for long-term, remote patient management under established US reimbursement codes. Adherium gets paid for sensor sales and by receiving monthly per-patient fees for generating and transmitting respiratory data.

"Ineffective usage and adherence tragically limit up to 90% of patients from receiving the full benefit of their transformative inhaled medications. With our groundbreaking Hailie sensors, we're championing proactive self-care, pioneering data-driven remote monitoring, and propelling enhanced outcomes at unparalleled lower cost," said Francis White, Adherium’s vice president of global business development.